This study concluded that SGLT-2 inhibitors show clear superiority in reducing cardiovascular deaths, all-cause deaths, hospitalization for heart failure (HF), and renal events among new ADAs as compared to other oGLDs. Here, SLC5A2 is linked to heart failure.